Inflammaging Biomarkers: What Chronic Inflammation Is Doing to Your Age

There's a slow fire burning inside you right now. You can't feel it. Your doctor probably hasn't mentioned it. And yet a growing body of research suggests it may be one of the most important forces shaping how fast you age and which diseases eventually catch up with you. Scientists call it inflammaging — a mashup of "inflammation" and "aging" that describes the low-grade, chronic inflammatory state that tends to build quietly in the body from your thirties onward.

This isn't the inflammation you feel when you sprain your ankle or fight off a cold. That kind is loud, purposeful, and temporary. Inflammaging is the opposite: silent, diffuse, and relentless. It hums along in the background, nudging your biology toward cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer. The frustrating part? Most standard blood panels barely scratch the surface of tracking it. But that's starting to change.

New research into inflammaging biomarkers is giving us sharper tools to measure what's actually happening at the cellular level — and, more importantly, to do something about it. This article breaks down what we know, what we don't, and how to figure out if chronic inflammation is quietly aging you faster than it should.

What Is Inflammaging, Really?

The term was coined by immunologist Claudio Franceschi in a landmark 2000 paper, and it hasn't left the longevity research conversation since. The basic concept: aging isn't just about things wearing out. It's also about your immune system getting louder in all the wrong ways.

Here's the origin story worth knowing. Franceschi and his colleagues were studying centenarians — people who lived past 100 — and noticed something unexpected. Many of them had elevated inflammatory markers. But they also had strong anti-inflammatory responses that seemed to balance things out. The idea of inflammaging grew from trying to understand why some people's inflammation becomes destructive while others seem to keep it in check. Think of it as the difference between a controlled campfire and an out-of-control wildfire. Same fuel source, very different outcomes.

At the cellular level, inflammaging is driven by several converging mechanisms:

• Senescent cells (cells that stop dividing but refuse to die) that secrete a cocktail of pro-inflammatory signals called the senescence-associated secretory phenotype, or SASP
• Mitochondrial dysfunction, which causes mitochondrial DNA to leak out and trigger immune alarms
• Gut microbiome changes that allow bacterial fragments (like lipopolysaccharide, or LPS) to seep into the bloodstream and activate inflammatory pathways
• Epigenetic drift, where the marks that control gene expression shift in ways that favor inflammatory gene activation
• Declining autophagy (your cells' built-in trash-removal system), which lets cellular debris accumulate and trigger chronic immune activation

All of these converge into a state of low-grade, systemic inflammation that doesn't resolve on its own. And unlike a flare of acute inflammation, it doesn't come with obvious symptoms. You just age faster.

The Inflammaging Biomarker Problem

Here's where it gets complicated. If chronic inflammation is this important, why isn't your doctor testing for it aggressively? The honest answer: the standard of care hasn't caught up with the research yet.

The most common inflammatory marker you'll see on a standard panel is high-sensitivity C-reactive protein (hs-CRP). CRP rises when your liver detects inflammatory signals in the blood, and elevated levels are associated with higher cardiovascular risk. It's useful. But it's also blunt. CRP can spike from a bad night's sleep or a sore muscle, and it doesn't tell you which cellular pathways are driving the fire or how deep it goes.

Beyond CRP: The Biomarkers Researchers Are Actually Excited About

A more complete picture of inflammaging requires looking at a panel of markers, not just one. Here's what the research points toward:

• Interleukin-6 (IL-6): One of the most studied pro-inflammatory cytokines (signaling proteins) in aging research. Chronically elevated IL-6 is associated with frailty, cognitive decline, and all-cause mortality. A 2019 analysis of data from the InCHIANTI study found that high IL-6 levels predicted disability and death in older adults independently of other risk factors.
• Tumor Necrosis Factor-alpha (TNF-alpha): Another pro-inflammatory cytokine that tends to rise with age and adipose (fat) tissue, particularly visceral fat around the organs. It promotes insulin resistance and is a known driver of metabolic disease.
• Interleukin-1 beta (IL-1β): A key driver of the NLRP3 inflammasome pathway, which is heavily implicated in cardiovascular disease and neurodegeneration. The CANTOS trial showed that blocking IL-1β with a drug called canakinumab reduced cardiovascular events independent of cholesterol levels — suggesting inflammation is its own independent risk factor.
• GDF-15 (Growth Differentiation Factor 15): An emerging "gerokine" (an aging-associated hormone-like protein) that rises sharply with biological age and stress. Some researchers now consider it one of the most sensitive systemic markers of cellular distress related to inflammaging.
• Soluble urokinase plasminogen activator receptor (suPAR): A newer biomarker released by activated immune cells. Research published in Nature Medicine in 2021 linked elevated suPAR to worsening kidney function, cardiovascular disease, and risk of multiple organ failures.
• Epigenetic inflammation clocks: Tools like the GrimAge and DunedinPACE clocks estimate biological age partly by measuring methylation patterns at inflammatory gene loci. These are arguably the most exciting development in inflammaging tracking because they integrate inflammation into a broader picture of biological aging speed.

What the Evidence Actually Shows About Inflammaging and Disease

The research linking chronic low-grade inflammation to age-related disease is substantial. Not speculative. Substantial.

• Cardiovascular disease: A 2017 landmark trial (CANTOS) showed that targeting the IL-1β inflammatory pathway with a biologic drug reduced major cardiovascular events by 15% in people who had already had a heart attack and had elevated hs-CRP — without touching cholesterol. This was the clearest human evidence yet that inflammation causes cardiovascular events, not just correlates with them.
• Neurodegeneration: Elevated systemic IL-6 and TNF-alpha are associated with accelerated cognitive decline. In Alzheimer's disease specifically, microglial cells (the brain's immune sentinels) become chronically activated, releasing inflammatory signals that accelerate amyloid buildup and neuronal death. Inflammaging in the periphery likely feeds this central neuroinflammation.
• Type 2 diabetes: Chronic low-grade inflammation drives insulin resistance. TNF-alpha interferes directly with insulin receptor signaling. Adipose tissue — particularly visceral fat — acts like an inflammatory organ, secreting cytokines that worsen metabolic function systemically.
• Cancer: The tumor microenvironment is profoundly shaped by inflammation. Chronic inflammatory states create conditions that favor tumor initiation, promotion, and progression. NF-kB (a master inflammatory transcription factor) is constitutively active in many cancers.
• All-cause mortality: A 2021 meta-analysis in Ageing Research Reviews found that higher levels of IL-6 and CRP were independently associated with increased all-cause mortality across multiple large cohort studies.

The Reality Check: What We Still Don't Know

Before you run out and order a full cytokine panel, a few honest caveats.

First, correlation is doing a lot of work here. We know elevated inflammaging markers associate with worse outcomes. We know much less about whether measuring and intervening on those markers in otherwise healthy middle-aged adults actually changes long-term outcomes. Most of the intervention trials have been in people who are already sick.

Second, cytokine levels are noisy. IL-6 fluctuates based on exercise, sleep, stress, meal timing, and a dozen other variables. A single measurement is a snapshot, not a movie. You need repeated measurements and context to draw useful conclusions.

Third, not all inflammation is bad. Hormetic stress — the kind from exercise, sauna, or short-term fasting — triggers acute inflammation that resolves and leaves you stronger. Chronically suppressing all inflammatory signaling is not the goal. The goal is resolving inappropriate, persistent, low-grade inflammation.

The internet wants a simple blood test that tells you your "inflammaging score" and a pill to fix it. The research is more nuanced than that. The most useful approach is a panel of markers, tracked over time, interpreted in clinical context.

Who Should Actually Be Paying Attention to This?

Not everyone needs to run a full inflammaging panel tomorrow. But you're probably in the population worth thinking about this if:

• You're 40 or older and interested in understanding your biological age vs. chronological age
• You have elevated hs-CRP on a standard panel and want to understand what's driving it
• You carry excess visceral fat (the kind that packs around your organs, not just under the skin)
• You have a family history of cardiovascular disease, type 2 diabetes, or neurodegenerative disease
• You experience unexplained fatigue, brain fog, or slow recovery — which can sometimes reflect a chronic inflammatory state
• You've had long COVID, which appears to involve sustained inflammatory dysregulation in a subset of people
• You're already tracking other longevity metrics and want a more complete picture

If none of those apply and you're a healthy 32-year-old, you probably don't need to obsess over your IL-6 levels just yet. But even then, the habits that drive inflammaging — poor sleep, excess visceral fat, sedentary behavior, ultra-processed food — are worth addressing early.

Risks, Confounders, and the Trap of Over-Medicalization

A brief, honest word on the risks of this space:

• Over-supplementing with anti-inflammatory compounds isn't benign. High-dose fish oil, NSAIDs, and some botanicals can interfere with normal immune signaling and healing responses.
• Chasing a single marker can create false reassurance. A low CRP doesn't mean you have no inflammaging. Context matters.
• Some interventions lower markers on paper without changing outcomes. Measuring less doesn't always mean having less of the problem.
• Cytokine suppression in the wrong context can impair immune surveillance against cancer and infection. This is why broad immunosuppression is a prescription-level decision, not a supplement protocol.

The right frame isn't "suppress inflammation." It's "resolve inappropriate chronic inflammation and support the body's regulatory systems." That distinction matters clinically.

How to Actually Track and Target Inflammaging with Healthspan

This is exactly the kind of thing that gets lost when you're seeing a GP for 15 minutes every year. It requires someone who's going to look at your full picture — labs, lifestyle, goals — and help you interpret what's actually going on.

Healthspan's Longevity Optimization protocol is built for this. It starts with comprehensive lab work that goes well beyond a standard annual physical — including inflammatory markers, metabolic panels, hormonal context, and biological age inputs — and pairs that with physician-guided interpretation. You're not getting a printout of numbers. You're getting a clinician who can look at elevated IL-6 alongside your visceral fat estimates, your sleep quality, and your glucose data, and help you understand what's actually driving what.

The clinical protocol includes:

• Baseline and follow-up lab panels that include inflammatory biomarkers (hs-CRP, IL-6, and others depending on clinical picture)
• Physician consultation to interpret results and build a targeted intervention strategy
• Access to prescription-level interventions when appropriate — including Metformin, which has evidence for reducing systemic inflammation and NF-kB signaling, and The Rapamycin Protocol, which targets mTOR-driven inflammation and cellular senescence
• Ongoing monitoring and protocol adjustments based on how your markers respond

For people with significant metabolic components to their inflammaging (visceral fat, insulin resistance, elevated fasting glucose), the SGLT2 Protocol and CGM Metabolic Protocol offer additional tools for addressing the metabolic drivers of chronic inflammation directly.

If you've been looking at your labs and feeling like something isn't being caught, this is what it looks like to actually investigate that. Start with a consultation and find out where your inflammaging markers actually stand.

Frequently Asked Questions About Inflammaging Biomarkers

What is inflammaging and how is it different from regular inflammation?

Inflammaging is a chronic, low-grade inflammatory state that develops gradually with age. Unlike acute inflammation — the kind that spikes when you get an infection or injury and resolves within days — inflammaging is persistent, systemic, and often asymptomatic. It doesn't resolve on its own and is driven by cellular changes like senescent cell accumulation, mitochondrial dysfunction, and gut barrier breakdown. Over years and decades, it contributes meaningfully to cardiovascular disease, neurodegeneration, diabetes, and cancer.

What blood tests measure inflammaging?

The most commonly used inflammaging biomarkers are high-sensitivity CRP (hs-CRP), interleukin-6 (IL-6), and TNF-alpha. More advanced panels may include IL-1β, GDF-15, and suPAR. Epigenetic clocks like GrimAge and DunedinPACE also incorporate inflammatory signals into biological age estimates. A single standard CRP is a starting point, but a meaningful inflammaging assessment requires multiple markers interpreted together and tracked over time.

Can you reduce inflammaging naturally?

Yes, meaningfully. Consistent resistance exercise, reducing visceral fat, optimizing sleep, eating a diet rich in whole foods and low in ultra-processed foods, and managing chronic stress all have documented effects on inflammatory markers. These aren't soft lifestyle suggestions — they move the numbers. For some people, they're sufficient. For others, particularly those with significant metabolic dysfunction or genetic risk, prescription-level interventions may add meaningful benefit on top of lifestyle changes.

Does metformin reduce inflammation?

There's solid mechanistic and human evidence that Metformin reduces markers of chronic inflammation, partly through its effects on AMPK activation and NF-kB inhibition, a master regulator of inflammatory gene expression. Clinical trials show reductions in CRP and IL-6 in people taking Metformin for metabolic indications. Whether these anti-inflammatory effects translate to meaningful longevity outcomes in metabolically healthy people is still being studied in trials like TAME (Targeting Aging with Metformin).

Does rapamycin reduce inflammaging?

Rapamycin inhibits mTORC1, a signaling complex that, when chronically overactive, promotes inflammation, suppresses autophagy, and accelerates cellular senescence. In animal studies, rapamycin consistently reduces markers of inflammaging and extends lifespan. In humans, it has shown reductions in inflammatory markers and improvements in immune function in older adults. The clinical evidence in younger, healthy humans is still developing, which is why physician supervision is essential for any rapamycin protocol.

What role does visceral fat play in inflammaging?

Visceral fat (the fat packed around your internal organs, not just under the skin) is one of the most potent drivers of inflammaging. It actively secretes pro-inflammatory cytokines including TNF-alpha, IL-6, and resistin. It also drives insulin resistance, which compounds the inflammatory signal. Reducing visceral fat — even a modest 5-10% reduction — consistently lowers systemic inflammatory markers. This is one reason metabolic health interventions are central to any serious inflammaging strategy.

Is inflammaging reversible?

Partially, and meaningfully so. Studies show that sustained lifestyle changes, particularly exercise and weight loss, can lower IL-6 and CRP levels over months. Prescription interventions like Metformin and rapamycin have also shown reductions in inflammaging markers. Whether you can fully "reverse" inflammaging or only slow its progression is still debated. The more useful framing: the earlier you intervene, the more room you have to shift the trajectory. Waiting until markers are dramatically elevated limits your options.